DEFIBROTIDE for Off label use: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where DEFIBROTIDE was used for Off label use.
Most Reported Side Effects for DEFIBROTIDE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 1,323 | 35.4% | 375 | 180 |
| Venoocclusive disease | 576 | 15.4% | 125 | 79 |
| Death | 463 | 12.4% | 463 | 148 |
| Multiple organ dysfunction syndrome | 372 | 10.0% | 337 | 125 |
| Venoocclusive liver disease | 355 | 9.5% | 272 | 73 |
| Intentional product use issue | 201 | 5.4% | 39 | 31 |
| Hypotension | 169 | 4.5% | 134 | 72 |
| Haemorrhage | 156 | 4.2% | 60 | 35 |
| Sepsis | 143 | 3.8% | 110 | 56 |
| Acute graft versus host disease | 140 | 3.7% | 69 | 56 |
| Gastrointestinal haemorrhage | 125 | 3.3% | 71 | 48 |
| Septic shock | 113 | 3.0% | 107 | 61 |
| Renal failure | 111 | 3.0% | 68 | 47 |
| Drug ineffective | 106 | 2.8% | 72 | 27 |
| Disease progression | 100 | 2.7% | 78 | 16 |
Other Indications for DEFIBROTIDE
Venoocclusive disease (1,325)
Venoocclusive liver disease (1,228)
Prophylaxis (1,073)
Product used for unknown indication (375)
Thrombotic microangiopathy (34)
Covid-19 (15)
Pulmonary veno-occlusive disease (8)
Hepatic failure (7)
Thrombosis (7)
Microangiopathy (6)
Other Drugs Used for Off label use
LENALIDOMIDE (5,767)
ECULIZUMAB (3,550)
CERTOLIZUMAB PEGOL (2,256)
ABOBOTULINUMTOXINA (2,170)
LEVETIRACETAM (2,161)
APREMILAST (1,995)
PROPRANOLOL (1,576)
CETIRIZINE (1,416)
HUMAN IMMUNOGLOBULIN G (1,129)
THALIDOMIDE (1,033)